Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 40 Colorectal Neoplasms 24 Carcinoma, Non-Small-Cell Lung 18 Rectal Neoplasms 14 Lung Neoplasms 13 Stomach Neoplasms 12 Esophageal Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 9 Esophageal Squamous Cell Carcinoma 9 Prostatic Neoplasms 8 Pancreatic Neoplasms 8 Neoplasm Metastasis 8 Colonic Neoplasms 8 Carcinoma, Hepatocellular 8 Adenocarcinoma Of Esophagus 8 Sarcoma 7 Ovarian Neoplasms 7 Neoplasms 6 Head and Neck Neoplasms 6 Urinary Bladder Neoplasms 5 Osteosarcoma 5 Liver Neoplasms 5 Kidney Neoplasms 4 Inflammatory Breast Neoplasms 4 Fallopian Tube Neoplasms 4 Carcinoma, Renal Cell 4 Breast Neoplasms, Male 4 Turcot syndrome 3 Multiple Myeloma 3 Locally Advanced Rectal Cancer 3

Interventions

Carboplatin 7 Pemetrexed 6 osimertinib 5 Drug Therapy 5 aflutinib 4 tislelizumab 3 anlotinib 3 Radiotherapy 3 Radiosurgery 3 Paclitaxel 3 Cisplatin 3 toripalimab 2 pembrolizumab 2 camrelizumab 2 apatinib 2 Surgical Procedures, Operative 2 S 1 (combination) 2 HM781-36B 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 trilaciclib 1 surufatinib 1 sintilimab 1 rezivertinib 1 lenvatinib 1 icotinib 1 famitinib 1 envafolimab 1 dacomitinib 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NSCLC × Neoadjuvant Therapy × Clear all

NCT07089199 2025-07-28

TitAN

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡